←
Siren Biotechnology, Inc.160 posts
Siren Biotechnology, Inc. avatar

Siren Biotechnology, Inc.

@SirenBio

Siren Biotechnology is the world's first #AAV #GeneTherapy company targeting #cancer.

◷ Joined June 2020▧ 113 Photos and videos
Siren Biotechnology, Inc. avatar
Siren Biotechnology, Inc.@SirenBio·Nov 9

@SirenBio is headed to #SNO2026 in Philadelphia this week! With SRN-101 entering the clinic for high-grade glioma, we’re looking forward to connecting with the neuro-oncology community working to bring better options to patients. Reach out if you’d like to meet with our team. See you in Philly! 👋

Post attachment
Siren Biotechnology, Inc. avatar
Siren Biotechnology, Inc.@SirenBio·Oct 20

Congratulations @SirenBio's SAB member Susan Kaech @Tcellogic on her election to @theNAMedicine for her outstanding scientific and technical achievements in the field of immunology!!!

I’m honored to be welcomed into @theNAMedicine. I share this recognition with all the students, postdocs, and colleagues in my lab. Your curiosity, hard work, and fearlessness in tackling big questions have driven everything we have achieved. Thank you. #NAMmtg

Post attachment
Siren Biotechnology, Inc. avatar
Siren Biotechnology, Inc.@SirenBio·Oct 16

We gave Léa Bouhelier-Gautreau from @kingscrowdinc a peak into our lab. 🎥 Léa spent a day with our team in San Francisco, watched how our science is done, and spoke with @Nicole_Paulk about where we’re headed. Her verdict on the people doing the work? “Very approachable, very fun, and at the same time extremely professional.” - We’ll take it! 😉 Two FDA-cleared INDs later, that same team is now bringing SRN-101 to the clinic. Watch the visit below. Let’s change the future of cancer care, together. youtube.com/watch?v=wmfmKDmC…

Siren Biotechnology, Inc. avatar
Siren Biotechnology, Inc.@SirenBio·Oct 14

📣 @SirenBio is pleased to announce the appointment of Dr. Peter Bross, MD, former Chief of the Oncology Branch at the FDA’s Center for Biologics Evaluation and Research (CBER), to our Clinical and Scientific Advisory Board! Dr. Bross brings more than 25 years of FDA experience reviewing novel oncology therapies, including gene and cell therapies, immunotherapies, and oncolytic viruses. His expertise comes at an important time as we advance SRN-101, our lead Universal #AAV Immuno #GeneTherapy candidate, into the clinic for recurrent high-grade glioma. Welcome, Dr. Bross! Read more at globenewswire.com/news-relea…

Post attachment
Siren Biotechnology, Inc. avatar
Siren Biotechnology, Inc.@SirenBio·Oct 8

@SirenBio is thrilled to welcome Ford H-Kirschenbaum to our Translational team! Ford brings 30 years of biotech experience building cell-based, biomarker, and bioanalytical assays for preclinical and clinical programs. At Siren, he is the driver of our translational assay development, in our own lab and with our external partners, as SRN-101 moves through the clinic. Welcome to the team, Ford!

Post attachment
Siren Biotechnology, Inc. avatar
Siren Biotechnology, Inc.@SirenBio·Sep 21

The @SirenBio team is headed to #Boston this week for Cell & Gene Therapy International @CellTherapyIC! Catch Nathalie Clement and Lauren Kelly on Friday, when they’ll be sharing a behind-the-scenes glimpse of the CMC and nonclinical strategy that led to Siren’s first IND. Don’t miss it!

Post attachment
Siren Biotechnology, Inc. avatar
Siren Biotechnology, Inc.@SirenBio·Sep 14

We are thrilled to welcome Mary Bearkland, Senior Director of Clinical Operations, to the @SirenBio team! Mary brings more than 25 years of clinical operations leadership, having directed Phase I–III trials from first-in-human studies to regulatory submission and contributed to two FDA-approved therapies. She will lead our clinical operations as we advance SRN-101, our Universal #AAV Immuno #GeneTherapy, through the clinic. Welcome to the team, Mary!

Post attachment
Siren Biotechnology, Inc. avatar
Siren Biotechnology, Inc.@SirenBio·Sep 3

🎉 Congratulations to Christine Xie on wrapping up a successful summer internship at @SirenBio! Christine, a student at @Stanford, spent the summer generating business development materials that guide Siren's strategic positioning as we advance our Universal #AAV Immuno #GeneTherapy for #Cancer. Her work will continue to serve the team long after her last day. Please join us in congratulating Christine and wishing her all the best as she heads back to Stanford this fall!

Post attachment